

**p21WAF1 (Tumor Suppressor Protein) Antibody - With BSA and Azide**  
**Mouse Monoclonal Antibody [Clone HJ21 ]**  
**Catalog # AH10999**

**Specification**

**p21WAF1 (Tumor Suppressor Protein) Antibody - With BSA and Azide - Product Information**

Application	IHC, IF, FC
Primary Accession	<a href="#">P38936</a>
Other Accession	<a href="#">1026</a> , <a href="#">370771</a>
Reactivity	Human, Mouse, Rat, Monkey, Chimpanzee
Host	Mouse
Clonality	Monoclonal
Isotype	Mouse / IgG1, kappa
Calculated MW	21kDa KDa

**p21WAF1 (Tumor Suppressor Protein) Antibody - With BSA and Azide - Additional Information**

**Gene ID** 1026

**Other Names**

Cyclin-dependent kinase inhibitor 1, CDK-interacting protein 1, Melanoma differentiation-associated protein 6, MDA-6, p21, CDKN1A, CAP20, CDKN1, CIP1, MDA6, PIC1, SDI1, WAF1

**Application Note**

IHC~~1:100~500  
IF~~1:50~200  
FC~~1:10~50

**Storage**

Store at 2 to 8°C. Antibody is stable for 24 months.

**Precautions**

p21WAF1 (Tumor Suppressor Protein) Antibody - With BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures.

**p21WAF1 (Tumor Suppressor Protein) Antibody - With BSA and Azide - Protein Information**

**Name** CDKN1A ([HGNC:1784](#))

**Function**

Plays an important role in controlling cell cycle progression and DNA damage-induced G2 arrest (PubMed: [9106657](http://www.uniprot.org/citations/9106657)). Involved in p53/TP53 mediated inhibition of cellular proliferation in response to DNA damage. Also involved in p53-independent DNA damage-induced G2 arrest mediated by CREB3L1 in astrocytes and osteoblasts (By similarity). Binds to and inhibits cyclin-dependent kinase activity, preventing

phosphorylation of critical cyclin-dependent kinase substrates and blocking cell cycle progression. Functions in the nuclear localization and assembly of cyclin D-CDK4 complex and promotes its kinase activity towards RB1. At higher stoichiometric ratios, inhibits the kinase activity of the cyclin D-CDK4 complex. Inhibits DNA synthesis by DNA polymerase delta by competing with POLD3 for PCNA binding (PubMed:<a href="http://www.uniprot.org/citations/11595739" target="\_blank">11595739</a>). Negatively regulates the CDK4- and CDK6-driven phosphorylation of RB1 in keratinocytes, thereby resulting in the release of E2F1 and subsequent transcription of E2F1-driven G1/S phase promoting genes (By similarity).

**Cellular Location**

Cytoplasm. Nucleus


**Tissue Location**

Expressed in all adult tissues, with 5-fold lower levels observed in the brain

**p21WAF1 (Tumor Suppressor Protein) Antibody - With BSA and Azide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

**p21WAF1 (Tumor Suppressor Protein) Antibody - With BSA and Azide - Images**

Formalin-fixed, paraffin-embedded Bladder Carcinoma stained with p21 Monoclonal Antibody (HJ21).

**p21WAF1 (Tumor Suppressor Protein) Antibody - With BSA and Azide - Background**

This MAb recognizes a 21kDa protein, identified as the p21WAF1 tumor suppressor protein. It is highly specific to p21 and shows no cross-reaction with other closely related mitotic inhibitors. p21WAF1 is a specific inhibitor of cdk s and a tumor suppressor involved in the pathogenesis of a variety of malignancies. The expression of this gene acts as an inhibitor of the cell cycle during G1 phase and is tightly controlled by the tumor suppressor protein p53. Its expression is induced by the wild type, but not mutant, p53 suppressor protein. Normal cells generally display a rather

intense nuclear p21 expression. Loss of p21 expression has been reported in many carcinomas (gastric carcinoma, non-small cell lung carcinoma, thyroid carcinoma).

**p21WAF1 (Tumor Suppressor Protein) Antibody - With BSA and Azide - References**

Krzywicka-Racka A & Sluder G J Cell Biol 194:199-207 (2011). | Folini M et al. Biochem Pharmacol 79:1781-90 (2010). |